Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate the Safety and Preliminary Efficacy of ATA3219, Allogeneic Anti-CD19 Chimeric Antigen Receptor T-cell Therapy, in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT06256484 is registered in ClinicalTrials.gov with Atara Biotherapeutics as lead sponsor.

NCT NCT06256484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06256484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate the Safety and Preliminary Efficacy of ATA3219, Allogeneic Anti-CD19 Chimeric Antigen Receptor T-cell Therapy, in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Lead sponsor
Atara Biotherapeutics
Phase
Phase 1
Overall status
Terminated
Start date
September 6, 2024
Completion date
March 30, 2025
Enrollment
1 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory b-cell non-hodgkin lymphoma